Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma
James William Smithy, Allison Betof, Sebastian Klobuch, Troels Holz Borch, Hannah L Kalvin, Nitzan Hasson, Shirly Grynberg, Rodabe Amaria, Juliane A Czapla, Megan D Schollenberger, Andrew J S Furness, Jessica C Hassel, Martin Wermke, Sidsel Pedersen, Inge Marie Svane, Antonio Ocejo, Elizabeth Buchbinder, Douglas B Johnson, Michael Postow, Cristy Los, Jose Lutzky, Evan J Lipson, Ryan J Sullivan, Harriet M Kluger, Katherine S Panageas, Marco Donia, John B A G Haanen, Alexander Noor Shoushtari · 2026
Read Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma by James William Smithy, Allison Betof, Sebastian Klobuch, Troels Holz Borch, Hannah L Kalvin, Nitzan Hasson, Shirly Grynberg, Rodabe Amaria, Juliane A Czapla, Megan D Schollenberger, Andrew J S Furness, Jessica C Hassel, Martin Wermke, Sidsel Pedersen, Inge Marie Svane, Antonio Ocejo, Elizabeth Buchbinder, Douglas B Johnson, Michael Postow, Cristy Los, Jose Lutzky, Evan J Lipson, Ryan J Sullivan, Harriet M Kluger, Katherine S Panageas, Marco Donia, John B A G Haanen, Alexander Noor Shoushtari (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13311620.txt.
Description
James William Smithy and co-authors in 2026 analyze a multi-center series on checkpoint drug treatment after cell therapy failure in advanced melanoma. No standard path exists once tumor-infiltrating lymphocyte therapy stops working.
Fourteen centers pooled records of patients who got checkpoint drugs both before and after the cell therapy. Among 133 patients whose response could be judged, 11 percent responded to the later checkpoint treatment in this series, with three full responses. Survival was estimated with standard time-to-event methods. The modest response rate frames what doctors can expect when they retry this drug class after cell therapy.
Catalog record
| CREATOR | James William Smithy, Allison Betof, Sebastian Klobuch, Troels Holz Borch, Hannah L Kalvin, Nitzan Hasson, Shirly Grynberg, Rodabe Amaria, Juliane A Czapla, Megan D Schollenberger, Andrew J S Furness, Jessica C Hassel, Martin Wermke, Sidsel Pedersen, Inge Marie Svane, Antonio Ocejo, Elizabeth Buchbinder, Douglas B Johnson, Michael Postow, Cristy Los, Jose Lutzky, Evan J Lipson, Ryan J Sullivan, Harriet M Kluger, Katherine S Panageas, Marco Donia, John B A G Haanen, Alexander Noor Shoushtari |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 18011 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |